Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nisha Ghatwai

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
BMC Cancer|January 22, 2020
IL-1-conferred gene expression pattern in ERα<sup>+</sup> BCa and AR<sup>+</sup> PCa cells is intrinsic to ERα<sup>-</sup> BCa and AR<sup>-</sup> PCa cells and promotes cell survivalAfshan F Nawas, Mohammed Kanchwala, Shayna E Thomas-Jardin, et al.
Cancer Immunology Research|March 20, 2026
Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cellsDavid Cunningham, Junquan Liu, Inci Cevher Zeytin, et al.
Cytometry. Part B, Clinical Cytometry|October 9, 2016
Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000Prashant R Tembhare, Sitaram Ghogale, Nisha Ghatwai, et al.
Nature Medicine|October 13, 2020
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysisAndras Heczey, Amy N Courtney, Antonino Montalbano, et al.
Journal for Immunotherapy of Cancer|January 12, 2025
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15Gengwen Tian, Amy N Courtney, Hangjin Yu, et al.
Nature Medicine|May 15, 2023
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
BMC Cancer|January 22, 2020
IL-1-conferred gene expression pattern in ERα<sup>+</sup> BCa and AR<sup>+</sup> PCa cells is intrinsic to ERα<sup>-</sup> BCa and AR<sup>-</sup> PCa cells and promotes cell survivalAfshan F Nawas, Mohammed Kanchwala, Shayna E Thomas-Jardin, et al.
Cancer Immunology Research|March 20, 2026
Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cellsDavid Cunningham, Junquan Liu, Inci Cevher Zeytin, et al.
Cytometry. Part B, Clinical Cytometry|October 9, 2016
Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000Prashant R Tembhare, Sitaram Ghogale, Nisha Ghatwai, et al.
Nature Medicine|October 13, 2020
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysisAndras Heczey, Amy N Courtney, Antonino Montalbano, et al.
Journal for Immunotherapy of Cancer|January 12, 2025
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15Gengwen Tian, Amy N Courtney, Hangjin Yu, et al.
Nature Medicine|May 15, 2023
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Pageof 1